Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Oncternal Therapeutics, Inc. | Financial_Report.xls |
| EX-32.1 - EX-32.1 - Oncternal Therapeutics, Inc. | a2223461zex-32_1.htm |
| EX-4.9 - EX-4.9 - Oncternal Therapeutics, Inc. | a2223461zex-4_9.htm |
| EX-10.39 - EX-10.39 - Oncternal Therapeutics, Inc. | a2223461zex-10_39.htm |
| EX-32.2 - EX-32.2 - Oncternal Therapeutics, Inc. | a2223461zex-32_2.htm |
| EX-10.25 - EX-10.25 - Oncternal Therapeutics, Inc. | a2223461zex-10_25.htm |
| EX-23.1 - EX-23.1 - Oncternal Therapeutics, Inc. | a2223461zex-23_1.htm |
| EX-31.2 - EX-31.2 - Oncternal Therapeutics, Inc. | a2223461zex-31_2.htm |
| EX-31.1 - EX-31.1 - Oncternal Therapeutics, Inc. | a2223461zex-31_1.htm |
| EX-10.29 - EX-10.29 - Oncternal Therapeutics, Inc. | a2223461zex-10_29.htm |
| 10-K - 10-K - Oncternal Therapeutics, Inc. | a2223461z10-k.htm |
| EX-10.34 - EX-10.34 - Oncternal Therapeutics, Inc. | a2223461zex-10_34.htm |
Exhibit 10.35
2015 Compensation Information for Registrant’s Executive Officers
The table below provides information regarding (i) the base salary of each executive officer of GTx, Inc. (the “Company”), effective as of January 1, 2015, with the exception of Dr. Wills, which is effective as of March 2, 2015, and (ii) the restricted stock units granted to each executive in February 2015:
|
Executive Officer |
|
Title |
|
2014 Annual |
|
2014 Restricted |
|
|
Marc S. Hanover |
|
Chief Executive Officer |
|
393,317 |
|
750,000 |
|
|
Robert J. Wills |
|
Executive Chairman of the Board |
|
200,000 |
|
1,000,000 |
|
|
Henry P. Doggrell |
|
Vice President, Chief Legal Officer and Secretary |
|
363,576 |
|
500,000 |
|
|
Jason T. Shackelford |
|
Sr. Director, Accounting & Corporate Controller and principal financing and accounting officer |
|
210,000 |
|
300,000 |
|
(1) Please see the Company’s current report on Form 8-K, filed on February 19, 2015 for additional information regarding the terms of these restricted stock units.